MannKind signs sale-leaseback agreement for inhaled insulin manufacturing site
The transaction will generate $102.25 million to support the company's product pipeline and scaling up commercial activities for Afrezza
MannKind, which makes an ultra rapid-acting inhaled insulin product for diabetes in the US, has entered into a sale-leaseback transaction to unlock value tied up in its Danbury, Connecticut manufacturing facility .
The company's CEO Michael Castagna said the $102.25 million transaction will support the company's "growing product pipeline" and its "targeted scale-up of Afrezza commercial activities and clinical trials".
The real property sale includes 263,900 sq. ft of manufacturing space, where it produces Afrezza (insulin human) Inhalation Powder, the company’s first US Food and Drug Administration-approved product and the only inhaled ultra rapid-acting mealtime insulin in the US.
It is also where MannKind is preparing to manufacture Tyvaso DPI (inhaled treprostinil), which is is currently being reviewed by the FDA for its potential to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, under its collaboration with United Therapeutics.
The transaction does not, however, extend to MannKind’s research and development facility.
Upon closing of the agreement, the endocrine and orphan lung diseases specialist will enter into a 20-year lease agreement with the purchaser — an affiliate of Creative Manufacturing Properties — with multiple renewal options available.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance